about
Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic reviewCH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer CellsTwenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results[Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib].Identification of DR9-restricted XAGE antigen on lung adenocarcinoma recognized by autologous CD4 T-cells.Whole blood interferon-gamma assay for baseline tuberculosis screening among Japanese healthcare students[Combination chemotherapy with carboplatin and etoposide for elderly patients aged 76 years or older with small cell lung cancer].Multicyclic dose-intensive chemotherapy supported by autologous blood progenitor cell transplantation for relapsed small cell lung cancer.Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer.Influence of altering administration sequence of docetaxel, gemcitabine and cisplatin in patients with advanced non-small cell lung cancer.Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: experience at a single institution.A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer.A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer.Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102.Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease.Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.Expression of minor histocompatibility antigen, HA-1, in solid tumor cells.Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades.Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells.Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation.An oral fluoropyrimidine agent S-1 induced interstitial lung disease: A case reportMagnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review.Lower lobe origin is a poor prognostic factor in locally advanced non-small-cell lung cancer patients treated with induction chemoradiotherapy.An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer.Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis.Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3.Induction chemoradiotherapy followed by surgical resection for clinical T3 or T4 locally advanced non-small cell lung cancer.Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group.Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell lung cancer.Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis.Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation.Endobronchial ultrasound-guided transbronchial needle aspiration of hilar and mediastinal lymph nodes detected on 18F-fluorodeoxyglucose positron emission tomography/computed tomography.Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung.Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer.
P50
Q27025724-C5F6247D-DC2E-4A83-A7EC-35CB07EDA481Q27852261-6CD70B3E-738C-4014-9D1B-A5F1EA4CE101Q28548485-D9B8D9F0-7F5B-40AF-8B9E-136B756FA1C9Q30886032-B3F1A18E-183F-44AB-9104-42754AB36222Q30926196-55215B42-05AD-4023-8F0E-599E0BFB047EQ33276419-49DDAD0A-BECF-499B-91F3-B74D2E86468FQ33295388-87D68C67-7D5C-461E-92F5-2530088C9640Q33342647-D6103921-F2D5-48BF-9459-EAE9865CCA7BQ33358011-65139623-E0DA-45C2-87C0-C014F35ED66CQ33362244-6C3285AA-C67E-40DD-8B37-AC3275D78E42Q33367665-28086BFA-904F-48CC-B58D-C96B2BEAF1C7Q33370883-3DB49E1D-0535-4E9C-B961-89C14AB850CEQ33370916-572AE5A7-6341-43BD-BFF6-B4B8D225BA26Q33371767-356CB4DE-6087-484D-A8A2-A76AA6BC8F32Q33374707-1B683B13-D7D4-4EEF-8D3E-03B69E8F4846Q33382289-D34C8154-04FF-4A9F-80E3-161C1EBDC711Q33389462-65717327-D022-4F72-9FF2-2BA1842907D6Q33433139-8C0F468D-662F-4131-9AA8-5175849D8AECQ33434764-CDEA4ADD-E68D-4E5A-BC88-A3B849A54894Q33565787-BD2CC1E0-C518-45A0-B79C-F321DBF58AD9Q33787355-A494658E-074F-40EB-916D-82870E644F75Q34124702-C95FD7C0-F07C-485D-A439-1B3E4BB7BFACQ34374754-6D3E6FA9-C35D-465C-88E5-C3E6E3177849Q34512158-08755A09-3055-46F6-96C2-ED0563A39677Q34672296-6C23DCCE-53D0-4D32-95BC-EBF76373109AQ35113385-BDFEB1D0-90DD-4344-9A4D-4B8D51B336F6Q35578537-7BF45CA7-1061-45D8-81D8-0C666770015FQ35753827-EBD407AA-B9AE-42DB-BDC3-4254934E7513Q35885842-C3BE9B74-B186-4C96-9614-07BC084979FCQ35896842-35850B27-B232-479E-A1DE-6015300C17CCQ36092880-312A9463-307E-41B9-B025-5787700944FCQ36113767-808538A9-0168-4E04-9723-2A9347EE9F28Q36140332-DF6B36E6-0C91-4A82-B4FF-77EA824F1C91Q36301778-E3AEE390-6106-4DDF-8520-0958A9C18A73Q36388912-B5D0C0BD-397A-48FB-8A7B-83219CBC8EC6Q36408862-E8EFE27B-C9D2-4530-8FEC-D2375C2A7A00Q36673653-E9E44AAB-56AB-4DD3-B02C-2A4703878667Q37058676-14576320-74E7-4115-AE0E-2AC6073D4F9BQ37378176-2A3A4DBE-9B41-4779-BB30-A119EC956163Q37384651-A79A817A-08AB-4E49-B4FC-7F2BB85BE27A
P50
name
Katsuyuki Kiura
@en
Katsuyuki Kiura
@nl
type
label
Katsuyuki Kiura
@en
Katsuyuki Kiura
@nl
prefLabel
Katsuyuki Kiura
@en
Katsuyuki Kiura
@nl